Studying the impact of novel therapies on tumors that have acquired resistance to CDK4/6i in vivo is challenging, as there are few if any animal models mimicking the most common clinical scenario – namely, a period of response to CDK4/6 inhibition followed by eventual tumor outgrowth. Here, CDK4 is linked to neoplasm.